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Abstract 
Background: Eosinophilic esophagitis (EoE) is a chronic inflammatory disease that has been known since the early 
1990s. Swallowed topical corticosteroids (STC) belong to the therapeutic cornerstones. We describe a delayed hyper-
sensitivity reaction to Jorveza®, a newly developed orodispersible budesonide tablet licensed for the treatment of 
eosinophilic esophagitis.
Case presentation: A 32-year-old Caucasian woman with EoE was newly treated with Jorveza®. Hours after the first 
intake, she felt a “strange pruritus” in the throat. This sensation worsened with each subsequent intake. On day 4 she 
developed oral mucosal symptoms (paresthesia of the tongue, sore and an itchy throat). Intraoral, throat and facial 
swellings, but no systemic reaction were observed. Patch testing using two commercial test series as well as the oro-
dispersible budesonide tablet revealed a strong sensitization, proving a T cell mediated allergy to budesonide.
Conclusions: Orodispersible budesonide is increasingly prescribed for the treatment of eosinophilic esophagitis. The 
development of oropharyngeal symptoms after initiating should alert the treating physician to the possibility of a 
hypersensitivity reaction.
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Background
Eosinophilic esophagitis (EoE) is an esophageal-
restricted, chronic inflammatory disease often associ-
ated with atopy. The prevalence of EoE is dramatically 
increasing and has currently reached values about 43 
individuals per 100,000 inhabitants [1]. EoE occurs in 
people of all ages [2], but is more prevalent among men 
and more common in Caucasians than in Africans [3]. 
Current therapeutic opinions are built on the three Ds: 
Drugs (swallowed topical corticosteroids [STC], proton-
pump inhibitors [PPIs] and biologics), Dietary restric-
tions to avoid alimentary antigens and, if the disease has 
led to the formation of strictures in advanced stages, 
endoscopic Dilation [4]. The effectiveness of STCs as 
induction treatment for acute EoE is well documented 
by a multitude of randomized controlled trials [5, 6]. The 
effect can be explained by a reduction of inflammatory 
cells, which leads to less fibrosis and also reverses IL13-
induced pathways [7].
Among STCs, fluticasone and budesonide are the most 
commonly used in the management of EoE [7]. Both are 
topically effective but have to be swallowed for the treat-
ment. In January 2018, the orodispersible budesonide 
tablet Jorveza® (budesonide, Dr. Falk Pharma GmbH, 
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Freiburg, Germany) was approved by European Medi-
cines Agency for the treatment of EoE, however, to date 
there is still no FDA approval. This orodispersible bude-
sonide tablet has a special galenic formulation designed 
to act locally at the site of inflammation in the esophagus 
[8]. Over a period of several minutes, the melting tablet 
dissolves in the mouth and the effervescent corpuscles 
contained in it stimulate the flow of saliva, which, with 
its adhesive properties, is an ideal medium for the active 
ingredient, as it transports the dissolved budesonide to 
the esophageal mucosa when swallowed, where it can 
exert its effects locally [8].
Case presentation
A 32-year-old Caucasian woman with atopy and relevant 
seasonal allergic rhinitis in the springtime was diagnosed 
EoE in 09/2018. Symptoms were somewhat atypical with 
postprandial coughing, especially after consumption of 
pasta and bread, regurgitation and intermittent dyspnea. 
After diagnosing EoE, treatment with fluticasone pow-
der was initiated and continued for 16 months. Induc-
tion therapy was started at 2x1000μg/day for 2 weeks, 
then reduced to 2x500μg/day and 3x250μg/day, respec-
tively. This therapy with fluticasone was in off-label pre-
scription. When the orodispersible budesonide tablet 
became available in Switzerland, a change in therapy 
was planned. The switch to orodispersible budesonide 
2x1mg/day is called day 1. Approximately 8 hours after 
the intake of the first effervescent tablet, a “strange pruri-
tus” was felt in the throat. This sensation worsened with 
each subsequent intake. Three days later (day 4) approxi-
mately 1 h after the intake of the evening dose symptoms 
progressed and the patient complained of dysphagia and 
dysarthria. On day 5, she consulted an otolaryngolo-
gist office because of persisting tongue-numbness and a 
burning throat sensation. In the evening of day 5 tongue, 
lips, face and the oral mucosa became swollen. She was 
unable to lie down because of swallowing difficulties due 
to increased mucus production. She felt a burning pain 
behind the sternum and experienced a feeling of tight-
ness. In the morning of day 6, she was referred to the 
emergency unit of the local hospital. The orodispersible 
budesonide was stopped. Clinical examination showed 
a generalized intraoral swelling and deep mucosal red-
ness. In addition, small transparent vesicles grouped in 
the middle of the hard palate were noticed. A smear test 
of the vesicles on the palate was positive for H. simplex 
virus type 1. CRP was slightly elevated (10,9 mg/l), eosin-
ophil count was normal (0.30G/l).
After treatment with clemastine (3 mg) and methyl-
prednisolone 40 mg i.v. facial and mucosal swelling sub-
sided within a few hours. A consecutive oral therapy with 
cetirizine 10 mg was prescribed. Swelling of the upper 
lips reoccurred the next day (day 7), but symptoms disap-
peared with oral prednisolone 50 mg/day over a period of 
2 days. Dose was tapered to 20 mg and finally to 10 mg/
day over a week. This dose was maintained for 2 weeks. 
Because allergy to budesonide was suspected, the patient 
was referred to an allergy workup.
The allergy workup was performed within 2 months 
after the reaction and included patch tests to Jorveza® 
and the corticosteroids tixocortol pivalate 1%, hydrocor-
tisone 1%, prednisolone 1%, budesonide 0.1%, amicinon-
ide 0.1%, triamcinolonacetonide 0.1%, dexamethasone 
0.1%, hydrocortisone-17-butyrate 0.1%, betametasone-
17-valerate 0.12% and clobetasol-17-propionate 0.25% 
and tixocortol-21-pivalate 3 μg/cm2, budesonide 1 μg/
cm2, hydrocortizone-17-butyrate 20 μg/cm2 (aller-
gEAZE® and T.R.U.E. TEST® SmartPractice, Hillerod, 
Denmark). Petrolatum was used as a negative control. 
Patch tests were removed 48 h after application and 
skin reactions were read after 48 and 72 h. Significantly 
positive reactions (++) with erythematous papules and 
isolated vesicules were observed to budesonide (tested 
twice) (Fig.  1(a), (b)) and the incriminated medication 
Jorveza® (Fig.  1(c)). Overnight after test application, a 
mild itchy flexural exanthema involving the insight of 
both elbows, neck, behind the ears and the décolleté area 
developed (Fig. 1(d)).
Since the patient subsequently developed coughing and 
dysphagia again as before EoE treatment, the therapy was 
switched back to the formerly well tolerated fluticasone 
on day 45 with 500 μg/day for 5 days following which the 
dose was raised to 1000 μg/day. No side effects have been 
observed since.
Retrospectively, the patient was already treated with 
inhaled budesonide (Symbicort®, AstraZeneca AB, Swe-
den) 17 years ago for 6 months, but did not develop any 
symptoms at that time.
Discussion and conclusions
To the best of our knowledge, this is the first report of 
a delayed hypersensitivity reaction to Jorveza®. Jorveza® 
a budesonide formulation specifically designed for the 
esophageal administration is the first drug approved by 
the regulatory authorities for the medical treatment of 
EoE and is now increasingly used for this indication.
Allergies to budesonide are rare, but have been pub-
lished in the literature [9]. Budesonide causes mostly 
delayed type hypersensitivity reactions as experienced 
by our patient. Maybe a reactivation of the herpes sim-
plex virus has triggered the hypersensitivity reaction to 
budesonide by T cells. Nevertheless, patch tests revealed 
a clear-cut monosensitization to budesonide and the oro-
dispersible budesonide tablet, respectively. How sensiti-
zation to budesonide occurred remains open. Based on 
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the patient’s history, inhaled budesonide was prescribed 
years before.
Following the index-reaction, the patient did toler-
ate prednisolone, topical clobetasole and fluticasone (Gr 
B). Therefore, except budesonide, CS for a systemic or 
topical therapy are available as well as fluticasone for the 
EoE treatment.
In conclusion, even though STCs are the most effec-
tive drugs to treat EoE efficiently, allergic reactions to 
STCs may hamper an optimal therapeutic course. When 
Fig. 1 48 h after application of patch tests significantly positive reactions (++) were observed with erythema, papules (vesicules) to (a) budesonide 
on panel 3 of the T.R.U.E. TEST®, b budesonide on the test series allergEAZE®, c Jorveza®. One day after test application, mild exanthemas with 
involvement of both elbows, neck and décolleté area were observed. The left elbow is shown here (d)
Page 4 of 4Andrist et al. BMC Gastroenterol          (2020) 20:419 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
developing oropharyngeal symptoms after the onset of 
Jorveza®, a hypersensitivity reaction must be considered.
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